# US 2015/0148285 A1 · Salt and protease-resistance of antimicrobial peptide and the manufacture thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148285 A1
- Document ID: US20150148285A1
- Status: Published application
- Kind: A1
- Application number: 14/273,064
- Filed: 2014-05-08
- Published: 2015-05-28
- Earliest claimed: 2013-11-28
- Assignees: National Tsing Hua University
- Applicants: National Tsing Hua University
- Inventors: Jya-Wei Cheng; Hui-Yuan Yu; His-Tsung Cheng
- Web page: https://patentgrep.com/patent/US20150148285A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61P 31/04: Antibacterial agents
- C07K 5/1019: {with the first amino acid being basic}
- C07K 7/06: having 5 to 11 amino acids
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides an antimicrobial peptide, wherein the amino terminal and/or carboxyl terminal of the peptide is linked with at least one artificial bulkyl amino acid to increase the salt resistance and protease resistance of the antimicrobial peptide. The antimicrobial peptide of the invention has a high salt resistance, a high protease resistance, and a low hemolytic activity, simultaneously.

## Claims

### Claim 1

A peptide of formula (I),
An-(Xp)-Bm
wherein
An and Bm selected from a group consisting of bulkyl amino acid and β-Nal;
p is from 1 to 9;
when n is 0, m is from 1 to 3; and
when m is 0, n is from 1 to 3.

### Claim 2 (depends on 1)

The peptide as claimed in claim 1, wherein the (Xp) of the formula (I) comprises positive-charged amino acids or uncharged amino acids.

### Claim 3 (depends on 1)

The peptide as claimed in claim 1, wherein the (Xp) of the formula (I) comprises at least two positive-charged amino acids.

### Claim 4 (depends on 2)

The peptide as claimed in claim 2, wherein the positive-charged amino acid is selected from a group consisting of lysine, arginine, and histidine.

### Claim 5 (depends on 2)

The peptide as claimed in claim 2, wherein the uncharged amino acid is selected from a group consisting of leucine, isoleucine, alaine phenylalanine, glycine, serine, threonine, cysteine, tyrosine, asparagine, and tryptophan.

### Claim 6 (depends on 1)

The peptide as claimed in claim 1, wherein the peptide of formula (I) has a length of not more than 12 amino acids.

### Claim 7

A method for enhancing salt resistance and protease resistance of a peptide, comprising:
providing a peptide, and
linking a bulkyl amino acid to the N-terminal and/or C-terminal of the peptide.

### Claim 8 (depends on 7)

The method as claimed in claim 7, wherein the bulkyl amino acid comprises Bal, 1-Nal, β-naphthylalanine, Dip, Bip, Ath, or Tbt.

### Claim 9 (depends on 7)

The method as claimed in claim 7, wherein the peptide is an antimicrobial peptide.

### Claim 10 (depends on 1)

An antibiotic for suppressing microorganism infection, comprises a peptide of claim 1 and a pharmaceutically acceptable adjuvant or carrier.
